Thirty-three states, the District of Columbia, and Puerto Rico will participate in CMS’ voluntary Cell and Gene Therapy (CGT) ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Controlling the activity of specific genes in the laboratory through the editing of their epigenetic marks is now a reality ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

Traditional ex-vivo CAR-T therapies require extracting a patient’s T cells, engineering them in specialized labs, and ...

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

A total of 33 states, plus the District of Columbia and Puerto Rico, agreed to participate in the U.S. CMS’ voluntary, outcomes-based program aimed at helping state Medicaid programs cover high-priced ...